Meningioma after immunomodulation for multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Alemtuzumab for multiple sclerosis: the new concept of immunomodulation
Alemtuzumab (Lemtrada®) is a humanized anti-CD52 IgG1 monoclonal antibody that depletes CD52-expressing cells from the circulation. Robust clinical and radiologic data, derived from clinical trials and long-term observational studies, indicate that alemtuzumab induces a marked immunosuppression related to the depletion of circulating T and B lymphocytes. However, recent advances suggest that th...
متن کاملMeningioma growth during interferon beta-1A treatment for multiple sclerosis.
Fleury Diagnostic Center, Section of Radiology, São Paulo SP, Brazil; Santa Casa de Misericórdia de São Paulo, Section of Radiology, São Paulo SP Brazil; Santa Casa de Misericórdia de São Paulo, Section of Neurology, São Paulo SP, Brazil; Santa Casa de Misericórdia de São Paulo, Section of Neurosurgery, São Paulo SP, Brazil; Santa Casa de Misericórdia de São Paulo, Section of Pathology, São Pau...
متن کاملMultiple sclerosis, immunomodulation, and immunizations: balancing the benefits.
Our patients with multiple sclerosis (MS) frequently inquire about the safety and efficacy of an annual influenza vaccination. Influenza remains a leading cause of mortality in the United States, with an estimated 20,000 deaths or more annually. Approximately 40% of all adults in the United States are vaccinated annually. The necessity of vaccination is particularly compelling for those with MS...
متن کاملImmune Rebound: Multiple Sclerosis after Treatment of Cushing’s disease
High cortisol level in endogenous Cushing’s syndrome suppresses the immune system and after treatment there may be an over activity of immune reaction leading to autoimmune diseases mostly thyroid and rheumatologic disorders. This is the second reported case of multiple sclerosis developing after treatment of Cushing’s syndrome. A 42-year old man is reported who presented with bone fracture and...
متن کاملMalignancies after mitoxantrone for multiple sclerosis
OBJECTIVE To assess the therapy-related risk of malignancies in mitoxantrone-treated patients with multiple sclerosis. METHODS This retrospective observational cohort study included all mitoxantrone-treated patients with multiple sclerosis seen at our department between 1994 and 2007. We collected follow-up information on medically confirmed malignancies, life status, and cause of death, as o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arquivos de Neuro-Psiquiatria
سال: 2012
ISSN: 0004-282X
DOI: 10.1590/s0004-282x2012000100017